Curzion Pharmaceuticals Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Curzion Pharmaceuticals Inc. - overview
Established
2009
Location
San Diego, CA, US
Primary Industry
Pharmaceuticals
About
Founded in 2019 and based in California, US, Curzion Pharmaceuticals Inc. is engaged in the development of an oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825).
Current Investors
Pappas Capital, RiverVest Ventures Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Curzion Pharmaceuticals Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Company Formation | Completed | Curzion Pharmaceuticals Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.